Fortress Biotech, Inc. (NASDAQ: FBIO)

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and developing drug assets to generate long term shareholder value through product revenue, equity holdings, dividends and royalty streams.

The company works with a network of key opinion leaders to identify promising product candidates and executes licensing or acquisition agreements with universities, research institutes and pharmaceutical firms such as City of Hope National Medical Center, Dana‑Farber Cancer Institute, Nationwide Children’s Hospital, Columbia University, the University of Pennsylvania, AstraZeneca, Dr. Reddy’s Laboratories and Sun Pharmaceutical Industries.

After securing rights, Fortress leverages its business, scientific, regulatory, legal and financial expertise to help its subsidiaries and partner companies advance their programs and pursue strategic collaborations, joint ventures, out licensing, sales or financing activities.

Its portfolio includes publicly traded partner companies such as Journey Medical Corporation, Mustang Bio, Avenue Therapeutics and Checkpoint Therapeutics (prior to its acquisition by Sun Pharma), as well as multiple private subsidiaries developing candidates in dermatology, oncology, rare diseases and other therapeutic areas.

Fortress generates revenue primarily from product sales through its subsidiaries and partner companies, such as the dermatology products marketed by Journey Medical Corporation.

It also earns equity based returns from its ownership stakes in publicly traded partner companies and receives dividend payments when those entities distribute profits.

Additionally, the company collects royalties, milestone payments and other consideration from licensing agreements and from the sale of priority review vouchers or other assets, as illustrated by the Cyprium Sentynl transaction and the Checkpoint acquisition.

These diverse streams, product revenue, equity appreciation, dividends and royalties, provide the company with multiple sources of cash flow.

• no_segments_reported.

Fortress operates in the highly competitive biopharmaceutical industry, where it faces rivalry from large multinational pharmaceutical firms, specialized biotechnology companies and academic research groups.

Its dermatology franchise, chiefly represented by Journey, competes in a fragmented market against companies such as Galderma Laboratories, Almirall, Leo Pharma, Mayne Pharma, Botanix Pharmaceuticals and Ortho Dermatologics.

In oncology and rare disease areas, the company contends with well capitalized competitors that have greater resources for clinical development, manufacturing and commercialization, although Fortress mitigates this through its partnership model and focus on niche indications.

The company's advantages lie in its ability to in license early stage assets, its scientific and regulatory expertise and its network of key opinion leaders that help accelerate development and reduce risk.

Fortress ultimately serves patients and healthcare providers who use the therapies developed by its subsidiaries and partners.

Its dermatology products are sold to retail pharmacies, dermatology clinics and hospitals for use by adult and adolescent patients with conditions such as acne, rosacea and hyperhidrosis.

In its oncology and rare disease programs, the company’s customers include treatment centers, specialist physicians and patients suffering from conditions like cutaneous squamous cell carcinoma, Menkes disease and graft versus host disease.

Specific collaborators that have provided licensed technology or research support include City of Hope, Dana‑Farber, Nationwide Children’s Hospital, Columbia University, the University of Pennsylvania, AstraZeneca, Dr. Reddy’s Laboratories and Sun Pharmaceutical Industries.